Deep Dives into Peptide Science
Research breakdowns, protocol design, and the latest findings from the world of peptide science. Written for researchers who care about the evidence.
GLP-1 Drugs Raised Severe Gut-Motility Risk by 37%. The Absolute Risk Stayed Low.
A 626,684-person matched cohort found a 37% higher relative risk of severe constipation, gastroparesis, or obstruction with GLP-1 therapies, but the absolute difference was small.
TE-8105 Could Stretch GLP-1 Injections to Every Two Weeks. The First Human Study Is Not an Efficacy Trial.
TE-8105 lasted about five days in the body and supported biweekly dosing in a 38-person first-human study. The weight-loss signal is not efficacy proof.
LTI-03 Reached Patients With Pulmonary Fibrosis. The Biomarker Signal Is Promising, Not Proof.
The first peer-reviewed patient study of inhaled LTI-03 found acceptable 14-day tolerability and shifts in fibrosis-linked biomarkers. It did not test whether patients breathe better or decline more slowly.
BGM0504 Lowered HbA1c by 2.48 Points. The Semaglutide Comparison Needs Context
A 64-person Phase 2 trial found a 2.48-point HbA1c drop at the highest BGM0504 dose. The signal is real, but claims that it beat semaglutide need context.
Oral Semaglutide Cut Heavy Drinking Days in a Phase 2 Trial. It Missed Its Primary Endpoint.
A new randomized trial found fewer heavy drinking days with oral semaglutide, but no significant benefit on its primary craving endpoint. The mixed result is the story.
A Peptide Spray Improved Diabetic Foot Infections. The Bacteria Told a More Complicated Story
A randomized trial found that topical peceleganan improved short-term clinical response in infected diabetic foot ulcers, while overall bacterial eradication remained uncertain.
CagriSema Beat High-Dose Semaglutide on HbA1c. The Margin Was Smaller Than the Headline
A 2,713-person phase 3 trial found CagriSema lowered HbA1c more than semaglutide 2.4 mg. The win was significant, but the average margin was 0.16 percentage points.
A Peptide Vaccine Made Humans Produce Antibodies Against IL-17A. That Is the Start, Not the Finish.
A 20-person Phase 1 trial found that FPP003 induced anti-IL-17A antibodies without severe or serious adverse events. Here is what that proves, and what it does not.
Can GLP-1 Drugs Slow Parkinson’s? The New Meta-Analysis Hides a Split Verdict
A positive 2026 meta-analysis clashes with a negative phase 3 trial and other reviews. Here is why the same GLP-1 evidence produces opposite Parkinson’s headlines.
DD01 Cut Liver Fat in 12 Weeks. Here's What the Phase 2 Trial Really Proved
In a randomized phase 2 trial, 76% of DD01 participants cut liver fat by at least 30% in 12 weeks. The efficacy signal was strong, but nausea and vomiting were common.
A Longer-Lasting Thymosin Beta-4 Repaired Heart-Attack Damage in Rats. Human Proof Is the Hard Part.
A new PEGylated thymosin beta-4 lasted four times longer and improved heart function after myocardial infarction in rats. The formulation is promising, but the human evidence is still mixed.